Insmed Surges to 292nd in Trading Volume with $31.9 Million Turnover

On July 11, 2025, Insmed (INSM) saw a significant increase in trading volume, with a turnover of $31.9 million, marking an 87.4% rise from the previous day. This surge placed Insmed at the 292nd position in terms of trading volume for the day. The stock price of Insmed rose by 1.57%, marking the third consecutive day of gains, with a total increase of 2.12% over the past three days.

Insmed's Chief Financial Officer, Sara Bonstein, sold 57,764 shares of the company's stock on July 7th. The shares were sold at an average price of $95.86, totaling $5,537,257.04. Following this transaction, Bonstein's holdings in the company decreased by 40.74%, leaving her with 84,017 shares valued at $8,053,869.62. This transaction was disclosed in a filing with the Securities and Exchange Commission.

Insmed reported its earnings on May 8th, with a loss of $1.42 per share for the quarter, missing the consensus estimate of $1.36 by $0.06. The company had a negative return on equity of 446.98% and a negative net margin of 265.93%. Despite the loss, Insmed's revenue for the quarter was $92.82 million, surpassing analyst estimates of $91.63 million. This represents a 22.9% increase in revenue compared to the same quarter last year.

Several institutional investors have recently adjusted their positions in Insmed. Darwin Global Management Ltd. increased its stake by 23.5% during the fourth quarter, now owning 12,960,538 shares worth $894,796,000. Norges Bank acquired a new position worth about $126,606,000 during the same period. Adage Capital Partners GP L.L.C. grew its position by 109.2% during the first quarter, now owning 3,446,944 shares worth $262,967,000. Nuveen LLC also acquired a new position worth about $88,351,000. Vanguard Group Inc. increased its stake by 6.3% during the fourth quarter, now owning 18,218,973 shares worth $1,257,838,000.

Analysts have recently commented on Insmed's stock. Bank of America raised its target price from $94.00 to $109.00 and maintained a "buy" rating. Mizuho increased its target price from $96.00 to $110.00 with an "outperform" rating. Morgan Stanley raised its target price from $90.00 to $102.00 with an "overweight" rating. Jefferies Financial Group reaffirmed a "buy" rating, while Leerink Partners increased its target price from $100.00 to $115.00 with an "outperform" rating. Currently, Insmed has a consensus rating of "Moderate Buy" with an average target price of $108.07.